HK INNO.N CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36,000 KRW | -0.83% |
|
-4.00% | -19.01% |
| Sales 2022 | 847B 613M | Sales 2023 * | 827B 599M | Capitalization | 1,020B 738M |
|---|---|---|---|---|---|
| Net income 2022 | 38B 27.51M | Net income 2023 * | 47B 34.03M | EV / Sales 2022 | 1.24 x |
| Net Debt 2022 * | 309B 223M | Net Debt 2023 * | 307B 223M | EV / Sales 2023 * | 1.6 x |
| P/E ratio 2022 |
27.6
x | P/E ratio 2023 * |
21.7
x | Employees | 1,695 |
| Yield 2022 * |
0.89% | Yield 2023 * |
0.89% | Free-Float | 51.69% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.83% | ||
| 1 week | -4.00% | ||
| Current month | -4.00% | ||
| 1 month | -4.51% | ||
| 3 months | -2.83% | ||
| 6 months | -19.10% | ||
| Current year | -19.01% |
1 week
35 950.00
38 850.00
1 month
34 550.0042 400.00
Current year
34 350.0047 450.00
1 year
27 900.0047 450.00
3 years
27 900.0080 300.00
5 years
27 900.0080 300.00
10 years
27 900.0080 300.00
| Managers | Title | Age | Since |
|---|---|---|---|
Seok-Hee Kang
CEO | Chief Executive Officer | 68 | - |
Ha-Won Lee
CMP | Compliance Officer | 45 | - |
Sang-Wook Park
CTO | Chief Tech/Sci/R&D Officer | 53 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sang-Hyun Yoon
BRD | Director/Board Member | 49 | - |
Jin-Ho Chai
BRD | Director/Board Member | 53 | - |
Seok-Hee Kang
CEO | Chief Executive Officer | 68 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 4 M€ | -4.41% | - | |
| 0.00% | 32 M€ | +5.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-04 | 36,000 | -0.83% | 86,003 |
| 24-07-03 | 36,300 | -3.71% | 152,222 |
| 24-07-02 | 37,700 | -2.08% | 146,083 |
| 24-07-01 | 38,500 | +2.67% | 226,391 |
| 24-06-28 | 37,500 | 0.00% | 199,016 |
End-of-day quote Korea S.E., July 03, 2024
More quotes
HK Inno.N Corp is a Korea-based company mainly engaged in the manufacture and sale of prescription drugs. The Company operates its business through three segments. The Prescription Drug segment is engaged in the manufacture and sale of hormone drugs, anticancer drugs, high blood pressure drugs, gastroesophageal reflux disease drugs, blood nutrient supplies, the circulatory system and others. The Health Beauty and Beverage (HB&B) segment is engaged in the manufacture and sale of products such as hangover relieving products, as well as health drinks and food products. The Other segment is engaged in the trademark royalties business and other services. The Company sells its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
36,000
KRW
Average target price
53,917
KRW
Spread / Average Target
+49.77%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -19.01% | 739M | |
| +6.97% | 71.73B | |
| +22.78% | 9.62B | |
| -23.21% | 4.38B | |
| +16.13% | 4.33B | |
| +19.42% | 3.73B | |
| +0.84% | 2.03B | |
| +6.54% | 1.92B | |
| -39.09% | 1.81B | |
| -46.93% | 1.66B |
- Stock Market
- Equities
- A195940 Stock
